Case report: Achieving significant tumor reduction in advanced pancreatic adenocarcinoma
Pancreatic cancer remains a highly malignant and challenging tumor with a dismal 5-year survival rate of only 13%. The majority of patients are diagnosed at advanced stages, where surgical options are limited, and prognosis is poor. Immunotherapy, particularly PD-1 inhibitors, has shown limited succ...
Saved in:
| Main Authors: | Hongying Liu, Yun Wang, Qian Zhang, Nengwen Ke |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1458517/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improving Outcomes in Pancreatic Adenocarcinoma: A Systematic Review of Immunotherapy in Multimodal Treatment
by: Paul-Cristian Borz, et al.
Published: (2025-06-01) -
Contribution of gut microbiome to pancreatic ductal adenocarcinoma development
by: D. V. Zaitsev, et al.
Published: (2025-05-01) -
Fibrolytic vaccination against ADAM12 reduces desmoplasia in preclinical pancreatic adenocarcinomas
by: Jing Chen, et al.
Published: (2024-10-01) -
Ectopic pancreatic adenocarcinoma in Meckel’s diverticulum: a case report
by: Shoichi Inokuchi, et al.
Published: (2024-02-01) -
Disulfidptosis: a novel gene-based signature predicts prognosis and immunotherapy efficacy of pancreatic adenocarcinoma
by: Jingyang Yin, et al.
Published: (2025-03-01)